Grifols (GRFS) Profit After Tax Growth (3y) (2013 - 2020)
Grifols (GRFS) Profit After Tax Growth (3y) (2013 - 2020) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
PAT Growth (3y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
76.51% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
133.08% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
42.47% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
19.53% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-51.87% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
-13.81% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
26.01% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
75.17% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Grifols |
- |
- |
- |
- |
| Date | Value |
|---|
| Mar 31, 2020 |
16.40% |
| Dec 31, 2019 |
48.75% |
| Mar 31, 2019 |
-30.16% |
| Dec 31, 2018 |
-11.05% |
| Sep 30, 2018 |
51.97% |
| Jun 30, 2018 |
12.49% |
| Mar 31, 2018 |
6.72% |
| Dec 31, 2017 |
-11.71% |
| Jun 30, 2017 |
936.66% |
| Mar 31, 2017 |
-4.57% |
| Dec 31, 2016 |
-39.48% |
| Sep 30, 2016 |
12.57% |
| Jun 30, 2016 |
9.86% |
| Mar 31, 2016 |
47.75% |
| Dec 31, 2015 |
114.32% |
| Sep 30, 2015 |
25.69% |
| Jun 30, 2015 |
20.08% |
| Mar 31, 2015 |
17.72% |
| Dec 31, 2014 |
337.06% |
| Sep 30, 2014 |
61.97% |
